{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06322238",
            "orgStudyIdInfo": {
                "id": "23-008706"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:",
            "officialTitle": "A Multi-gene Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice: Open-label, Mayo Clinic Multisite (Mankato-Rochester Primary Care), Controlled, Implementation Study Taking the Results of the PREPARE Study Into Minnesota (PREPARE-Mayo)",
            "acronym": "PREPARE-Mayo",
            "therapeuticArea": [
                "Other"
            ],
            "study": "pharmacogenetic-panel-to-prevent-adverse-drug-reactions-in-daily-primary-care-practice"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-09",
            "studyFirstSubmitQcDate": "2024-03-13",
            "studyFirstPostDateStruct": {
                "date": "2024-03-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Isa J. Houwink",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug')."
        },
        "conditionsModule": {
            "conditions": [
                "Pharmacogenomic Drug Interaction",
                "Side Effect of Drug",
                "Ineffective Drug Action",
                "Drug Metabolism, Poor, CYP2D6-Related",
                "Drug Metabolism, Poor, CYP2C19-Related"
            ],
            "keywords": [
                "pharmacogenomics",
                "PGx",
                "CPIC",
                "primary care",
                "drug metabolism",
                "side effects",
                "ineffectiveness",
                "PREPARE-Mayo"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 66,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "PGx testing arm",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Diagnostic Test: PGx panel test"
                    ]
                },
                {
                    "label": "Delayed PGx testing arm",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Diagnostic Test: PGx panel test"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "PGx panel test",
                    "description": "In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mankato), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.",
                    "armGroupLabels": [
                        "Delayed PGx testing arm",
                        "PGx testing arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Drug Reaction (ADR)",
                    "description": "The count of participants who experience any of the following ADR's: muscle aches, falling, tripping, fainting, palpations, emotional changes, or physical changes",
                    "timeFrame": "48 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PREPARE-MAYO Clinicians' and pharmacists' Questionnaire.",
                    "description": "The 29-item PREPARE-MAYO Clinicians' and pharmacists' Questionnaire measures the Experience and Attitude, Knowledge, Knowledge testing and Needs assessment of clinicians and pharmacists. Each item is scored from 1 (disagree) to 4 (agree). Total possible scores range from 29 to 116, with lower scores indicating less knowledge and higher scores indicating more knowledge.",
                    "timeFrame": "48 weeks"
                },
                {
                    "measure": "Patient-Reported Outcomes Measurement Information System (PROMIS-10) Global Health Questionnaire",
                    "description": "The 10-item PROMIS Global Health measures general, physical, mental and social health. Each item is scored from 1 (poor health) to 5 (excellent health). Total possible scores range from 10 to 50, with lower scores indicating worse state of health and higher scores indicating greater state of health.",
                    "timeFrame": "48 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n1. Subject must be \u2265 18 years old\n2. Subject must receive a 1st prescription (meaning no known prescription for this drug in the preceding 12 months) for a drug included in Table 1, which is prescribed to them in routine primary care.\n3. Subject is able and willing to take part and willing to be followed up on for 48 weeks\n4. Subject is able to donate saliva\n5. Subject has signed informed consent\n6. Subject meets requirement for computer access implying computer literacy as measured by active use of the patient portal or their email\n\nExclusion Criteria:\n\n1. For the investigational arm only: Previous (direct-to-consumer, or clinical) pharmacogenomic testing that includes any of the genes included in the Focused Pharmacogenomics Panel\n2. Pregnant or lactating (to be verbally confirmed with the patient)\n3. Life expectancy estimated to be less than three months as determined by patient receiving hospice care\n4. Duration of index drug total treatment length is planned to be less than seven consecutive days.\n5. Current inpatients\n6. Unable to consent to the study\n7. Unwilling to take part\n8. Subject has no permanent address\n9. Subject has no current primary care provider\n10. Subject is, in the opinion of the study coordinator after discussion with participating clinician/pharmacist/investigator, not suitable to participate in the study\n11. Patient has a diagnosis of stage 4 or 5 chronic kidney disease (CKD) or is receiving dialysis\n12. Patients with advanced liver failure (stage Child-Pugh C) or a diagnosis of liver cirrhosis\n13. History of a liver transplant or an allogeneic hematopoietic stem cell transplant\n14. DNA sample collected that requires retesting in the event that DNA collected was not sufficient for testing as determined by the laboratory",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Isa Houwink, M.D., Ph.D.",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55902",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elisa Houwink, MD, PhD",
                            "role": "CONTACT",
                            "phone": "507-319-2037",
                            "email": "houwink.elisa@mayo.edu"
                        },
                        {
                            "name": "Mary Johnson",
                            "role": "CONTACT",
                            "email": "johnson.mary15@mayo.edu"
                        },
                        {
                            "name": "Jessica Wright, PharmD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Deidentified individual data that supports the results will be shared beginniing 9 to 36 months following publication provided the investigator who proposes the use of the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data sharing use /sharing agreement with Mayo Clinic and the PI.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF"
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000064420",
                    "term": "Drug-Related Side Effects and Adverse Reactions"
                }
            ],
            "ancestors": [
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M30303",
                    "name": "Drug-Related Side Effects and Adverse Reactions",
                    "asFound": "Adverse Drug Reactions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}